TIGIT

Latest news

Tag

Triple-Drug Regimen with Tiragolumab and Atezolizumab Shows Superior Response in First-Line Esophageal Cancer: The MORPHEUS-EC Trial

The phase 1b/2 MORPHEUS-EC trial demonstrates that adding the anti-TIGIT antibody tiragolumab to atezolizumab and chemotherapy significantly improves objective response rates (67.7%) in patients with previously untreated, locally advanced o

Jan 6, 2026

news

Dual TIGIT/PD‑1 Blockade with Domvanalimab + Zimberelimab Plus FOLFOX Shows Promising Activity in First‑Line Advanced Gastric and GEJ Adenocarcinoma

A phase 2 arm of the EDGE‑Gastric trial reports a 59% confirmed objective response rate and median PFS 12.9 months with domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX in untreated HER2‑negative advanced gastric

Nov 13, 2025Sign in to read

news

Dual TIGIT and PD‑1 Blockade with Domvanalimab + Zimberelimab plus FOLFOX Shows Promising Activity in First‑Line Advanced HER2‑Negative Gastroesophageal Adenocarcinoma

In a phase 2 cohort (EDGE‑Gastric A1), domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX produced a 59% ORR, median PFS 12.9 months and median OS 26.7 months in 41 previously untreated HER2‑negative gastroesophage

Nov 12, 2025